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Endovenous laser ablation of varicose veins with
the 1470-nm diode laser
Thomas Schwarz, MD, Eva von Hodenberg, MD, Christian Furtwängler, BS, Aljoscha Rastan, MD,
Thomas Zeller, MD, and Franz-Josef Neumann, MD, Bad Krozingen, Germany
Background: Endovenous laser ablation (EVLA) is one of the most accepted treatment options for varicose veins. In
previous studies conducted with a laser at 810 to 1320 nm, paresthesia, pain, and ecchymosis were common adverse
effects. We hypothesized that a lower linear endovenous energy density (LEED), as used with 1470-nm diode laser fibers,
would lead to a reduction in adverse events.
Methods: We conducted a prospective, nonrandomized observational cohort study of 312 consecutively treated lower
limbs legs in 286 patients. Of these, a bare laser fiber (ELVeS-plus kit) was used to treat 168 legs in 150 patients (group
1), and a radial fiber (ELVeS-radial kit) was used in 144 legs in 136 patients (group 2). Laser treatment was performed
in the great saphenous vein. Follow-up for all patients was 3 months. The primary end point was the occurrence of
ecchymosis and bruising. This was correlated to the reduced LEED needed with the 1470-nm diode laser.
Results:Laser fiber (odds ratio [OR], 22.3; 95% confidence interval [CI], 20.2-24.5) and body mass index (OR, 0.35; 95%
CI, 0.15-0.55) were identified as independent parameters for LEED. In group 2 compared with group 1, LEED in the
great saphenous vein could be reduced from 79.4  9.1 to 57.4  10 J/cm (P < .0001). LEED was an independent
parameter for skin bleeding (OR, 1.04; 95% CI, 1.017-1.058). Ecchymosis and bruising were significantly less frequent
in group 2 than in group 1 (P < .0001). The need for analgesia was low, with 103.08  15.34 mg diclofenac-sodium in
group 1 vs 82.08  18.86 mg in group 2 (P < .04). Occlusion with elimination of reflux was achieved in 100% of group
1 and group 2 (P < 1). No recanalization occurred at follow-up.
Conclusion: Endovenous laser treatment of varicose veins in the great saphenous vein with the 1470-nm diode laser is safe
and highly effective. The lower energy level needed using the radial laser fiber significantly minimized adverse effects
compared with the bare laser fiber. ( J Vasc Surg 2010;51:1474-8.)Varicose veins are a common disease in Western coun-
tries, with a prevalence of up to 20% in men and 25% in
women.1 In the last decade, the spectrum of treatment for
varicose veins has been broadened. New, less invasive treat-
ment options than surgery have been introduced, such as
ultrasound-guided foam sclerotherapy, radiofrequency ab-
lation, and endovenous laser ablation (EVLA). The first
report on EVLA was published in 1999.2 Several studies
have since been published reporting different regimens for
the energy per surface area (J/cm), pulse duration, and
wavelength of the laser. The published data on efficacy and
safety of laser treatment arise from a laser with a wavelength
between 810 and 1320 nm and show 90% to 100% occlu-
sion.3-7
A new-generation laser with a longer wavelength of
1470 nmwas recently introduced. Some have hypothesized
that efficacy would be higher due to higher specificity for
the interstitial water in the vessel wall of this laser and lower
absorption by hemoglobin7-9; however, data are scarce. We
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1474assessed the efficacy and safety of the new laser with
1470-nm wavelength in a prospective study in consecutive
patients and compared efficacy and safety of the 1470-nm
bare fiber vs the 1470-nm radial laser fiber. We also studied
the lower linear endovenous energy density (LEED) used
with the different 1470-nm laser fibers and its correlation
to the observed postinterventional skin bleeding.
METHODS
Patients. Our prospective, nonrandomized study in-
cluded consecutive patients who underwent EVLA of in-
competent varicose veins. All patients who presented at our
vascular diagnostics unit were referred by their general
practitioners for symptoms suggestive of symptomatic var-
icose veins. All patients gave informed consent for the
procedure. The study protocol was approved by the insti-
tutional ethics committee of the University of Freiburg
Medical School.
All patients were seen by a vascular physician who
specialized in venous disease. The baseline examination
included history, physical examination, and venous duplex
ultrasound imaging of the lower extremity veins. Inclusion
criteria for the study were varicose veins with ultrasound-
documented reflux in the great saphenous vein (GSV)
judged suitable for endovenous treatment. We excluded
patients from EVLA treatment if the average size of the
varicose vein was2 cm or if there was extreme tortuosity.
Examinations and procedures. Venous ultrasound
imaging was performed at each presentation (HDI 5000,
linear array, 4-7 MHz [ATL, Bothell, Wash] and zone
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using a standardized examination protocol.10,11 The veins
were examined with the patient upright to determine ve-
nous reflux, defined as retrograde flow of 0.5-second
duration.12 The CEAP classification of varicose veins was
determined for all patients.13,14
The bare and radial fibers that were used in this study
are suitable for the 1470-nm diode laser (Cerelas D, Bio-
litec). The 600 m ELVeS-plus kit consists of a bare fiber,
a guiding catheter of 70 cm or 100 cm length with guid-
ance markings for cm or controlled pull-back, a 5 Fr sheath,
a 0.035 J tip guide wire with length of 150 cm, and a 19G
7cm entry needle. The ELVeS-radial kit consists of a 600
m radial fiber with guidance markings, a 6 Fr sheath with
12 cm introducer length, a 0.0038 J-tip guide wire with 45
cm length, and a 19G  7 cm entry needle. The bare fiber
releases its energy only in a straight, forward direction,
whereas the energy from the radial fiber is emitted in a 360°
manner from a nontraumatic fiber tip. Laser treatment
started while a second venous ultrasound imaging study
was performed of the area of treatment. The entire proce-
dure was guided by venous ultrasound imaging.
The varicose vein was punctured at the distal insuffi-
ciency point. The entry of the varicose vein into the deep
vein was controlled by ultrasound guidance. The placement
of the laser fibers was performed according to the manufac-
turer’s guidelines.
A tumescent local anesthesia was given consisting of 25
mL of 2%Ultracaine (Sanofi-Aventis, Frankfurt, Germany),
25 mL of sodium carbonate, and 0.5 mL of epinephrine
diluted in 500 mL of cooled saline along the perivenous
space with the use of ultrasound guidance. Laser energy was
delivered at 15 W using the bare fiber and 10 W using the
radial fiber. The varicose vein was treated to approximately
1 cm above the skin entry site. LEED (J/cm), a surrogate
marker of fluence (J/cm2), was calculated as described
elsewhere.15,16 The applied laser energy was 100 J/cm for
the bare fiber vs 80 J/cm for the radial fiber at the proximal
10 cm above the knee, 80 vs 60 J/cm at the following
length above the knee, and 60 J/cm for both fibers below
the knee. Laser energy application was controlled, modify-
ing the velocity until withdrawal of the catheter. To control
pullback we used in both groups catheter equipped with a
ruler. In the area of the saphenofemoral junction the cath-
eter was placed on the level of the inflow of the inferior
superficial epigastric vein. After the procedure, venous out-
flowwas checked immediately in the proximal deep veins by
ultrasound imaging. Persistent reflux in tributaries or below
the treated vein was checked, and additional treatment with
foam sclerotherapy was applied if needed.
Immediately after the procedure, prophylaxis of venous
thromboembolism with subcutaneous enoxaparin (40 mg)
was started and continued for the next 5 days.
Compression therapy with a graduated class II stocking
at 30 to 40 mm Hg was initiated immediately. Patients
were to wear the stockings for 24 hours for 1 week, then
during the day for a further 3 weeks. Diclofenac sodium, a
nonsteroidal anti-inflammatory drug was prescribed (75mg, 3 to 5 days, twice daily) for optional use. The patient
was told to resume routine daily activities but to avoid
strenuous exercise for about 1 week.
Follow-up examinations were performed at 1 week, 1
month, and 3 months after laser therapy and included
clinical examination and venous ultrasound imaging of the
treated leg. Any clinical sign of hematoma or ecchymosis
was noted and summarized as skin bleeding. Signs for
phlebitis were also checked.
The aim of the ultrasound imaging was to examine the
treated vein and the surrounding area for venous reflux and
the treated vein for recanalization and also to exclude deep
vein thrombosis (DVT) in the leg. All patients were re-
quested to present in our vascular unit or contact us by
phone if symptoms of DVT or pulmonary embolism (PE)
developed. The diagnostic criterion for thrombosis was the
lack of compressibility of 1 or more segments of the veins of
the lower extremity. We treated DVT and PE according to
standard protocols. We also asked for the amount of pain
relief medication required after the procedure.
Study end points. The primary study end point was
the occurrence of ecchymosis, bruising, and the reduction
of LEED. The primary efficacy end point was ultrasound-
proven elimination of venous reflux in a treated varicose
vein by laser after 3 months. Secondary efficacy and further
safety end points after 3 months were: (1) ultrasound-
proven occlusion of the treated vein (2) and exclusion of
recanalization of the treated vein segments; (3) DVT, su-
perficial vein thrombosis (SVT), or clinical PE, as defined
by objective testing; (4) death from any cause; and (5)
clinical complaints during procedure, such as pain, and
paresthesia.
Statistical analysis. Differences between the study
groups were noted by analysis of variance, 2 test, and
Fisher’s exact test, as appropriate. Values of P  .05 were
considered significant. A logistic regression analysis was
used to assess the risk for skin bleeding events in the study
groups adjusted for sex, age, body mass index, LEED, and
treated leg. Results of the regression model are given as
odds ratio (OR) and 95% confidence intervals (CI). To
identify factors that correlate with LEED, we performed a
multivariable analysis using the general linear model. As
independent variables, this multivariable model included
age, sex, body mass index, treated side and laser fiber.
Calculations were performed with SPSS 11.5 software
(SPSS, Chicago, Ill).
RESULTS
Patients. From August 2007 until May 2009, we
treated 312 legs in 286 patients with the 1470-nm diode
laser. Energy was delivered intraluminally. Between August
2007 and October 2008, we used the bare fiber in 168 legs
in 150 patients (group 1), and between November 2008
and May 2009, we used the radial fiber in 144 legs in 136
patients (group 2). Procedures in patients who required
bilateral treatment were performed at different sessions
with a time interval 4 weeks.
JOURNAL OF VASCULAR SURGERY
June 20101476 Schwarz et alThe baseline characteristics of the two study groups are
reported in Table I. The group 2 patients were significantly
younger than group 1 patients.
Four patients in group 1 (4 limbs, 2.38%) were lost to
the 3-month follow-up evaluation due to patient refusal. In
group 2, 3-month follow-up data were missing in eight
patients (8 limbs/5.55%) owing to one death and seven
refusals. All patients lost to follow-up were contacted by
phone. The reason not to present in our unit was due to a
long distance between the patient and our hospital – and
due to lack of complaints. Thus, the 3-month follow-up
data could be completed in 300 of 312 limbs (96.2%).
Endovenous procedure. The total average time of
the procedure, beginning with the initial ultrasound imag-
ing until leaving the examination table was 46.85  11.39
minutes in group 1 and 45.72 12.63 minutes in group 2,
which was not significant. Delivery of LEED was signifi-
cantly lower in group 2 in laser treatments of the GSV (57.4
vs 79.4 J/cm group 1; P .0001). As independent param-
eters for LEED, we could identify laser fiber (OR, 22.3;
95% CI, 20.17-24.49), and body mass index (OR 0.35,
Table I. Patient characteristics according to limb
treatment by bare or radial fiber
Variable Bare fiber Radial fiber P
Patients, No. 168 144
Sex
Male 57 41
Female 112 103 .3
Age, y
Mean  SD 61  13.8 57  13.9 .005
Range 16-88 23-85
BMI, kg/m2
Mean  SD 26.5  6.33 26.3  4.67 .8
Range 17.3-56.2 18.5-45.9
Treated side
Right 89 71 .7
Left 79 73
CEAP, No. (%)
C2 100 (59.5) 84 (58.3) .9
C3 22 (13.1) 29 (20.1) .09
C4 31 (18.5) 25 (17.4) .8
C5 3 (1.8) 3 (2.1) .9
C6 12 (7.1) 3 (2.1) .06
BMI, Body mass index; SD, standard deviation.
Table II. A, Multivariate analysis for linear endovenous
energy density
Variable Adjusted difference (95% CI) P
Age, years 0.003 (0.079 to 0.085) .946
Sex, M/F 0.547 (2.867 to 1.772) .643
Side, R/L 2.306 (4.423 to 0.188) .033
BMI, kg/m2 0.349 (0.146 to 0.551) .001
Laser fibera 22.331 (20.167 to 24.496) .0001
BMI, Body mass index; CI, confidence interval.
aBare fiber vs radial fiber.95%CI, 0.15-0.55). Compared with group 1, LEED in theGSV in group 2 could be reduced from 79.4 9.1 to 57.4
 10 J/cm (P  .0001; Table II). All results are given in
Table III.
Safety outcomes. Any skin bleeding was seen signifi-
cantly less frequently in group 2 than in group 1 (P 
.0001; Table II). Skin bleeding in group 2 were mostly
puncture-related after applying tumescent anesthesia or
after introducing the 6F sheath. In group 1, large areas of
skin bleeding were frequently seen around the treated area.
No hematoma could be detected in all sonographical ex-
aminations in both groups. All bleeding-related skin alter-
ations disappeared completely in both groups after 3
months. LEED was an independent parameter for skin
bleeding (OR, 1.04; 95% CI, 1.017-1.058).
We used ultrasound imaging to diagnose postproce-
dural DVT in two patients in group 1 (1.30%), comprising
an ascending asymptomatic thrombosis with extension into
the common femoral vein in a 29-year-old woman after 1
week and a symptomatic femoral thrombosis with proven
PE in a 50-year-old obese woman (BMI, 56.15 kg/m2) at
28 days. The latter patient showed no sign of venous
thromboembolism at the 1-week follow-up. All patients
with DVT were treated successfully after an initial treat-
ment with full-dose anticoagulation therapy. No venous
thromboembolism occurred in group 2.
Superficial vein thrombosis (SVT) was diagnosed in
three patients in each group (1.9%). SVT was seen distally
to the treated segments or in tributaries of the thigh with
Table II. B, Regression analysis for risk of skin bleeding
Variable OR (95% CI) P
LEED 1.037 (1.017 to 1.058) .0001
Age, years 0.982 (0.962 to 1.004) .105
Sex, M/F 0.760 (0.421 to 1.371) .362
Side, R/L 0.799 (0.460 to 1.389) .427
BMI 1.013 (0.960 to 1.068) .648
BMI, Body mass index; CI, confidence interval; LEED, linear endovenous
energy density; OR, odds ratio.
Table III. Intervention according to limb treatment
with bare or radial fiber
Variable Bare fiber Radial fiber P
Patients, No. 168 144
Combined treatment,a
No. (%)
102 (60.7) 108 (75.0) .02
Operation time, min
Mean  SD 46.85  11.39 45.72  12.63 .39
Range 20-120 15-75
LEED GSV J/cm
Mean  SD 79.4  9.1 57.4  10.0 .0001
Range 48.5-118.3 15.4-89.3
GSV, Great saphenous vein; LEED, linear endovenous energy density; SD,
standard deviation.
aLaser plus foam sclerotherapy.hampered or blocked outflow.
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up. One patient in group 2 died of ventricular fibrillation
not related to the procedure.
Pain relief medication was significantly lower in group 2
(82.08  18.86 mg vs 103.08  15.34 mg of diclofenac
sodium, P  .04). All outcomes of both study groups are
reported in Table IV.
Efficacy outcomes. The primary efficacy end point of
our study did not differ significantly between the two
groups. In group 1, we achieved elimination of venous
reflux and immediate occlusion in 168 of 168 limbs (100%)
after one laser procedure. Elimination of reflux occurred
after the second procedure in one patient with a vein
diameter of 2 cm. In group 2, elimination of reflux was
achieved in all treated limbs as well (100% occlusion). In
both groups, no recanalization of the treated vein was
diagnosed with ultrasound imaging during follow-up. After
3 months, all venous ulcers were sealed in both groups (14
total: 12 in group 1 and 2 in group 2).
DISCUSSION
The aim of endovenous procedures is to establish a less
invasive, highly effective, and safe therapeutic option in the
treatment of varicose veins compared with surgery. The
efficacy results of our study show superiority of the
1470-nm diode laser to most published data obtained with
an 810- to 980-nm diode laser, in which energy is known to
be absorbed by deoxygenated hemoglobin.8 The recently
introduced 1470-nm laser acts directly on the vessel wall
through the absorption by the interstitial water. In addi-
Table IV. Outcome at 3-month follow-up evaluation
according to limb treatment by bare or radial fiber
Bare fiber Radial fiber P value
Patients, No. 168 144 .5
Deaths 3 months,
No. (%)
0 (0%) 1 (0.7%)
3-month results,
No. (%)
Occlusion 168 (100) 144 (100) .99
Side effects, No.
(%)
Deep vein
thrombosis
2 (1.2) 0 (0) .5
Pulmonary
embolism
1 (0,6) 0 (0) .6
Phlebitis 3 (1.8) 3 (2.1) .8
Paresthesia 0 (0) 0 (0) .99
Ecchymoses,
hematoma
141 (83.9) 92 (63.9) .0001
Analgesia use,a
mean  SD,
mg
103.08  15.34 82.08  18.86 .04
No need for
analgesia, No.
(%)
36 (21.4) 51 (35.4)
SD, standard deviation.
aDiclofenac sodium.tion, the lately developed radial fiber emits light at 360°,causing a homogenous alteration of the vein wall. These
direct effects induce complete occlusion of the vein in
approximately 100% of the treated vein segments and
thereby eliminate venous reflux.
In endovenous procedures, the amount of energy ap-
plied on a vessel segment depends on the wattage (J/s) and
the duration of treatment. The amount of energy given was
an independent predictor of vessel occlusion.16 It was
reported that 80 J/cm is required to gain treatment suc-
cess.17,18 These results, however, concerned the hemoglobin-
specific laser wavelength. Our results with the water-
specific 1470-nm laser show that in both groups, LEED
could be further reduced without loss of efficacy.
Comparison of bare and radial laser fibers. Our
results show no statistically significant differences in efficacy
between the treatment groups. With regard to procedure
safety, treatment with the radial fiber showed significantly
less skin bleeding events and necessitated less pain relief. In
group 2 in our study compared with other studies, LEED
was much lower, with a mean of 58.94 J/cm for GSV.
Pannier et al,19 who published the first data on 100
patients treated with a 1470-nm diode laser, demonstrated
a 100% occlusion rate after 1 year, but their drop-out rate of
17% was quite high.19 They treated the patients with a bare
fiber, as in group 1 of our study. In the Pannier et al study,
mean LEED was 107 J/cm for GSV. Safety results in their
study showed a paresthesia rate in the treated area of 9.5%
persisting after 6 months and 7.6% after 1 year.19 They
suggested a correlation between LEED and patient dis-
comfort.
In our study, the lower incidence of side effects, such as
skin bleeding in the radial fiber group, demonstrates a
correlation with the lower energy applied. This was also
reflected in the lower need for analgesia in the radial fiber
group. The lower incidence of adverse events with the
radial fiber is probably because perforation of the vein is
very unlikely. This is suggested by a study using an ex vivo
model in a cow’s foot.20
Study limitations. We present a short-term follow-up
of 3 months, during which time no recanalization occurred
of treated varicose veins. Thus, the long-term success com-
pared with other treatment options, such as surgery, re-
mains to be assessed by future studies.
Another limitation is the nonrandomized nature of our
study, which resulted in differences in baseline characteris-
tics between the two groups, particularly with respect to the
type of veins treated. Nevertheless, a correlation of a lower,
but still highly effective LEED, and the statistically signifi-
cant reduction of side effects prevailed even after stratifica-
tion for the type of vein treated.
CONCLUSION
We demonstrate that treatment of varicose veins with
1470-nm endovenous laser therapy is safe and effective.
Compared with the bare fiber, the radial fiber reduces the
energy requirement, adverse side effects, and patient dis-
comfort at a comparable success rate. Thus, for future
studies of the long-term outcome of endovenous proce-
JOURNAL OF VASCULAR SURGERY
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laser combined with radial fiber appears to be the most
promising device.
AUTHOR CONTRIBUTIONS
Conception and design: TS
Analysis and interpretation: TS, EH, CF
Data collection: TS, CV
Writing the article: TS
Critical revision of the article: TS, TZ, FN
Final approval of the article: TS, EH, CF, AR, TZ, FN
Statistical analysis: AR
Obtained funding: Not applicable
Overall responsibility: TS
REFERENCES
1. Maurins U, Hoffmann BH, Lösch C, Jöckel KH, Rabe E, Pannier F.
Distribution and prevalence of reflux in the superficial and deep venous
system—results from the Bonn vein study, Germany. J Vasc Surg
2008;48:680-87.
2. Bone C. Tratamiento endoluminal de las varices con laser de Diodo.
Estudio preliminary. Rev Pathol Vasc 1999;5:35-46.
3. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of
saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003;14:
991-96.
4. Agus GB, Mancini S, Magi G, IEWG. The first 100 cases of Italian
Endovenous-laser Working Group (IEWG). Rationale and long-term
outcomes for the 1999-2003 period. Int Angiol 2006;25:209-15.
5. Ravi R, Rodriguez-Lopez JA, Trayler EA, Barrett DA, Ramaiah V,
Diethrich EB. Endovenous ablation of incompetent saphenous veins: a
large single-center experience. J Endovasc Ther 2006;13:244-8.
6. Sharif MA, Soong CV, Lau LL, Corvan R, Lee B, Hannon RJ. En-
dovenous laser treatment for long saphenous incompetence. Br J Surg
2006;93:831-35.
7. Proebstle TM, Moehler T, Gul D, Herdemann S. Endovenous treat-
ment of the great saphenous vein using a 1320 nmNd: YAG laser causes
fewer side effects than using a 940 nm diode laser. Dermatol Surg
2005;31:1678-83.8. Van den Boos RR, Kockaeret MA, Neumann HAM, Nijsten T. Tech-
nical review of endovenous laser therapy for varicose veins. Eur J
Endovasc Surg 2008;35:88-95.
9. Kabnick LS. Outcome of different endovenous laser wavelengths for
great saphenous vein ablation. J Vasc Surg 2006;43:88-93.
10. Schwarz T, Schmidt B, Schellong SM. Inter observer agreement of
complete compression ultrasound for clinically suspected deep vein
thrombosis. Clin Appl Thromb Hemost 2002;8:45-9.
11. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettelr W,
et al. Complete compression ultrasonography of the leg veins as a single
test for the diagnosis of deep vein thrombosis. Thromb Haemost
2003;89:228-34.
12. Jeanneret C, Labs KH, Aschwanden M, Bollinger A, Hoffmann U,
Jäger K. Physiological reflux and venous diameter change in the proxi-
mal lower limb veins during a standardised Valsalva manoeuvre. Eur J
Vasc Endovasc Surg 1999;17:398-403.
13. Porter JM, Gregory LM. Reporting standards in venous disease. J Vasc
Surg 1995;21:635-45.
14. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner
RL, et al. Revision of the CEAP classification for chronic venous
disorders: consensus statement. J Vasc Surg 2004;40:1248-52.
15. Proebstle TM, Moehler T, Herdemann S. Reduced recanalization rates
of the great saphenous vein after endovenous laser treatment with
increased energy dosing: definition of a threshold for the endovenous
fluence equivalent. J Vasc Surg 2006;44:834-9.
16. Proebstle TM, Krummenauer E, Gul D, Knop J. Nonocclusion and
early reopening of the great saphenous vein after endovenous laser
treatment is fluence dependent. Dermatol Surg 2004;30:174-8.
17. Timperman PE. Prospective evaluation of higher energy great saphe-
nous vein endovenous laser treatment. J Vasc Intervent Radiol 2005;
16:791-4.
18. Timpermann PE, SichlauM, Ryu RK. Greater energy delivery improves
treatment success of endovenous laser treatment of incompetent saphe-
nous veins. J Vasc Intervent Radiol 2004;15:1061-3.
19. Pannier F, Rabe E, Maurins U. First results with a new 1470-nm diode
laser for endovenous ablation of incompetent saphenous veins. Phle-
bology 2009;24:26-30.
20. Sroka R, Weick K, Da Conta A, Scheibe S, Srika I, Winter S, et al.
Investigations on the acute effects of circumferential laser light energy
application for endovenous laser treatment. Edizioni Minerva Medica,
Torino 2009 [in press].Submitted Nov 12, 2009, accepted Jan 7, 2010.
